Tirzepatide vs Retatrutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Mounjaro, Zepbound
A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials.
Also: LY3437943, Triple G
A triple agonist targeting GLP-1, GIP, and glucagon receptors. Represents the next evolution beyond dual agonists like tirzepatide, showing unprecedented weight loss in trials.
Key Comparison Insights
- Tirzepatide is FDA approved, while Retatrutide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Tirzepatide has stronger research evidence (FDA Approved) compared to Retatrutide (Human Trials).
- Both are GLP-1 class medications compared in weight management studies.
Detailed Comparison
| Attribute | Tirzepatide | Retatrutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Tirzepatide activates both GLP-1 and GIP receptors, providing synergistic effects on appetite suppression, insulin secretion, and metabolic regulation. The dual mechanism enhances glucose-dependent insulin release while reducing glucagon and slowing gastric emptying. | Retatrutide activates three receptors: GLP-1 for appetite suppression and glucose control, GIP for enhanced insulin response and metabolic effects, and glucagon for increased energy expenditure and fat oxidation. The triple mechanism provides synergistic effects. |
| Common Dosing | 5-15 mg weekly (after titration) Once weekly | 4-12 mg weekly Once weekly, same day each week |
| Administration | Subcutaneous injection weekly | Subcutaneous injection weekly |
| Typical Duration | Long-term / chronic use | Long-term use expected |
| Best Time to Take | Morning, same day each week | Morning, same day each week |
Possible Side Effects May vary by individual |
|
|
| Research Summary | SURMOUNT trials showed average weight loss of 20-26% body weight. SURPASS-2 showed superior A1C reduction compared to semaglutide. Demonstrates significant improvements in cardiovascular risk factors including blood pressure and lipids. | Phase 2 trials showed up to 24% weight loss at 48 weeks, the highest seen in any obesity drug trial. Studies demonstrate significant improvements in metabolic markers, liver fat reduction, and glycemic control. Phase 3 trials underway. |
Frequently Asked Questions: Tirzepatide vs Retatrutide
What is the difference between Tirzepatide and Retatrutide?
Tirzepatide is a weight loss peptide that a dual gip/glp-1 receptor agonist representing the next generation of incretin-based therapies. shows superior weight loss compared to semaglutide in head-to-head trials. Retatrutide is a weight loss peptide that a triple agonist targeting glp-1, gip, and glucagon receptors. represents the next evolution beyond dual agonists like tirzepatide, showing unprecedented weight loss in trials. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Tirzepatide or Retatrutide?
Neither is universally "better" - the choice depends on your specific goals. Tirzepatide is typically used for weight loss purposes, while Retatrutide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Tirzepatide and Retatrutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Tirzepatide and Retatrutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Tirzepatide and Retatrutide is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.